Tandem autologous-haploidentical transplantation is a feasible and effective program for refractory Hodgkin lymphoma

Mariotti, Jacopo; Bramanti, Stéfania; Devillier, Raynier; Fürst, Sabine; El‐Cheikh, Jean; Sarina, Barbara; Granata, Angela; Faucher, Catherine; Harbi, Samia; Morabito, Lucio; Weiller, Pierre Jean; Chabannon, Christian; Mokart, Jamel; Mineri, Rossana; Carlo‐Stella, Carmelo; Santoro, Armando; Blaise, Didier; Castagna, Luca

doi:10.1038/s41409-017-0032-1

Cited by 3 publications

(2 citation statements)

References 18 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median follow-up was 44 months and 3-year PFS, OS, incidence of relapse, and NRM after the tandem were 53%, 73%, 34%, and 13%, respectively. A similar result was reported by Mariotti et al in another study (115). The results suggest that this might be an effective treatment for a high-risk population.…”

Section: Tandem Autologous-allogeneic Transplantationsupporting

confidence: 90%

Advances in the treatment of Hodgkin lymphoma: Current and future approaches

et al. 2023

View full text Add to dashboard Cite

Hodgkin lymphoma (HL) is a rare type of lymphoma with unique histologic, immunophenotypic, and clinical features. It represents approximately one-tenth of lymphomas diagnosed in the United States and consists of two subtypes: classical Hodgkin’s lymphoma (cHL), which accounts for majority of HL cases, and nodular lymphocyte predominant Hodgkin lymphoma represent approximately 5% of Hodgkin lymphoma cases. From this point, we will be focusing on cHL in this review. In general, it is considered a highly curable disease with first-line chemotherapy with or without the addition of radiotherapy. However, there are patients with disease that relapses or fails to respond to frontline regimens and the standard treatment modality for chemo sensitive cHL is high dose chemotherapy followed by autologous hematopoietic stem cell transplant (AHSCT). In recent years, targeted immunotherapy has revolutionized the treatment of cHL while many novel agents are being explored in addition to chimeric antigen receptor (CAR) T-cell therapy which is also being investigated in clinical trials as a potential treatment option.

show abstract

Section: Tandem Autologous-allogeneic Transplantationsupporting

confidence: 90%

Advances in the treatment of Hodgkin lymphoma: Current and future approaches

et al. 2023

View full text Add to dashboard Cite

show abstract

“…HDT/ASCT has been traditionally reserved for patients with chemosensitive relapse due to a more favorable outcome for those achieving a complete metabolic response at the time of PET scan [26]. In the pre-novel agent's era, only a small fraction of patients refractory to first-line ST were rescued by strategies employing tandem autologous [27] or tandem autologous-allogeneic transplantation [28,29]. Since the introduction of novel agents as a second-or third-salvage line of therapy, the best consolidation strategy has been a matter of debate.…”

Section: Discussionmentioning

confidence: 99%

Outcome of High-Dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma after Different Numbers of Salvage Regimens

Mariotti,

Ricci,

Giordano

et al. 2024

Cells

Self Cite

View full text Add to dashboard Cite

The introduction of novel drugs (PD-1 inhibitors and/or brentuximab vedotin) into salvage regimens has improved the response rate and the outcome of patients with relapsed/refractory Hodgkin lymphoma. However, the impact of new drugs on the outcome has not been adequately investigated so far. We retrospectively analyzed 42 consecutive patients treated at our institution with high-dose chemotherapy/autologous stem cell transplantation after either one standard chemotherapy represented by BEGEV (n = 28) or >1 salvage therapy (ST) comprising novel drugs (n = 14). With a median follow-up of 24 months, the 2-year cumulative incidence of relapse was similar between the two cohorts: 26% for 1 ST and 18% for >1 ST (p = 0.822). Consistently, overall survival and progression-free survival did not differ among the two groups: 3-year overall survival was 91% and 89% (p = 0.731), respectively, and 3-year progression-free survival was 74% and 83% (p = 0.822) for only one and more than one salvage regimens, respectively. Of note, the post-transplant side effects and engraftment rates were similar between the 1 ST and >1 ST cohorts. In conclusion, consolidation with high-dose chemotherapy/autologous stem cell transplantation is a safe and curative option, even for patients achieving disease response after more than one rescue line of therapy.

show abstract